|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||9.09 - 9.09|
|52 Week Range||3.93 - 56.88|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO , Jan. 22, 2020 /CNW/ - FSD Pharma Inc. (HUGE) (HUGE.CN) (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has appointed Larry Kaiser , MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma's Scientific Advisory Board (SAB). Dr. Kaiser is currently the Managing Director with the Healthcare Industry Group at Alvarez and Marsal, a leading global professional services firm.
TORONTO , Jan. 17, 2020 /CNW/ - FSD Pharma Inc. (HUGE.CN) (HUGE.CN) (FRA: 0K9) ("FSD Pharma" or the "Company") is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari , along with the founders, members of the Company's Board of Directors, members of the leadership team, early investors, advisors, and other stakeholders, will ring the Nasdaq Stock Market opening bell on Wednesday, January 22, 2020, at 9:30 am ET. The Opening Bell Ringing Ceremony will be held at Nasdaq's MarketSite in New York City and will be webcast live beginning at 9:20 am ET via the following link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony and live streaming will be available on Facebook at the following link: http://Facebook.com/Nasdaq. "It will indeed be a unique privilege for me to ring the opening bell at Nasdaq to commence trading in the presence of FSD Pharma's extended family and friends," said Raza Bokhari , MD, Executive Co-Chairman and CEO.
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2020) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9), a specialty, biotech pharmaceutical R&D company, has started trading on the Nasdaq Capital Market under the symbol "HUGE". FSD Pharma is focused on developing, over time, a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of ...
FSD Pharma Inc (CSE: HUGE) (OTC: FSDDF ) said Monday that its Class B Subordinate Voting Shares have been accepted for listing on the NASDAQ Capital Market under the ticker "HUGE." The stock ...
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") today announced that its Class B Subordinate Voting Shares (the "Shares") have been approved for listing on the NASDAQ Capital Market ("NASDAQ") under the symbol ‘HUGE’. Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020.
Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020 . The Company's Shares will continue to be listed on the Canadian Securities Exchange under the symbol 'HUGE'.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") today announced the appointments of three key executives: Donal Carroll, Chief Financial Officer. Mr. Carroll previously served as interim CFO; Sandra Lottes, Pharm D, Vice President & Head of Clinical Research of FSD Pharma’s BioSciences Division; and Shahzad Shah, Chief Operating Officer of FV Pharma.
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), a specialty, biotech pharmaceutical R&D company, reports its application to list its Class B Subordinate Voting Shares on the Nasdaq Capital Market has been approved by Nasdaq and the company anticipates trading on Nasdaq to begin shortly. FSD Pharma is focused on developing a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of ...
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF ) said Monday it has obtained approval for its Class B subordinate shares to list on the Nasdaq Capital Market. The company hasn’t provided a specific date for when ...
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Nasdaq has approved its application to have its Class B Subordinate Voting Shares (the "Shares") listed on the Nasdaq Capital Market ("Nasdaq"). FSD Pharma expects the Shares to commence trading on Nasdaq in the near future.
Mr. Bokhari will be available during the day on December 17 for one-on-one meetings. Mr. Bokhari's presentation will be webcast live and available for replay on the 'Events and Presentations' section of the 'Investors' page of the FSD Pharma website, www.fsdpharma.com, or via https://www.webcaster4.com/Webcast/Page/2038/32606.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Edward Brennan, MD, President, BioSciences Division, will present an overview of the Company at the 12th Annual LD Micro Main Event Investor conference at 12:20 p.m. PT/3:20 p.m. ET on Wednesday, December 11, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will be held December 10-12, 2019. Dr. Brennan will also host one-on-one meetings with investors throughout the day.
As cannabis earnings season continues, Benzinga took a look at the quarterly prints from four companies in the sector Monday. 4Front Ventures Reports $6.86M Quarterly Net Loss 4Front Ventures Corp. (CSE: ...
These financial results are unaudited, are prepared in accordance with International Financial Reporting Standards (IFRS) and are reported in Canadian dollars. The Company intends to initiate Phase 1 first-in-human safety and tolerability trials for its lead candidate, PP 101 micro-PEA during 1Q20.
TORONTO , Nov. 4, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (OTCQB:FSDDD) (0K9.F) ("FSD" or the "Company") announces that it has closed a second tranche of its previously announced private placement (the "Private Placement"), and has now raised total gross proceeds of CAD $4,596,285 from investors, including members of senior management and the Board of Directors, issuing an aggregate of 228,671 class B subordinate voting shares (the "Shares"). The Shares issued to purchasers in Canada will be subject to a four-month hold period, in accordance with applicable Canadian securities laws. The Company expected to close the Private Placement by October 31, 2019 , however, it has elected to extend the Private Placement to accommodate potential additional interest from institutional grade investors.
TORONTO , Oct. 23, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") announces that an amended and restated management's discussion and analysis for the year ended December 31, 2018 (the "Amended 2018 MD&A") has been filed on SEDAR to better comply with National Instrument 51-102 – Continuous Disclosure Obligations. The Amended 2018 MD&A was prepared following a continuous disclosure review by the Ontario Securities Commission ("OSC") of the Company's disclosure record. The Amended 2018 MD&A was filed to address comments received from OSC staff and in order to improve the Company's disclosure.
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDD) announced that its Class B shares, which trade on the OTCQB, will have a new symbol FSDDD for a period of 20 business days until November 13th, at which time the symbol will revert back to FSDDF. The temporary change is protocol for stocks that trade on US exchanges that undergo structural events, such as ...